Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate 400mg, 600mg and 800mg Tablets Clinical Trial Formulation (CTF) Versus the To-be-marketed Formulation (TBM) in Healthy Male and Female

NCT02283840 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT02283840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate 400mg, 600mg and 800mg Tablets Clinical Trial Formulation (CTF) Versus the To-be-marketed Formulation (TBM) in Healthy Male and Female
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2007
Enrollment
60 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy